Quest Diagnostics
Quest Diagnostics (NYSE: DGX) provides clinical laboratory testing, anatomic pathology services and diagnostic insights to physicians, hospitals, patients, health plans, employers, government agencies, pharmaceutical companies and other healthcare organizations. Its testing spans routine and specialized services,… From the company’s description.
In fiscal 2025, Quest Diagnostics reported revenue of $11.04B, up 11.8% from fiscal 2024, and net income of $1.05B. Its operating margin was 14.1%, and operations generated $1.89B in cash. Over the twelve months to Sep 30, 2026, revenue was $11.84B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Quest Diagnostics does
In the company’s own words
Quest Diagnostics (NYSE: DGX) provides clinical laboratory testing, anatomic pathology services and diagnostic insights to physicians, hospitals, patients, health plans, employers, government agencies, pharmaceutical companies and other healthcare organizations. Its testing spans routine and specialized services, including molecular diagnostics, oncology, neurology, genetics, infectious disease, cardiometabolic health and women’s health; it also offers laboratory management, population health, healthcare IT and clinical-trial services. The company operates through Diagnostic Information Services, its laboratory testing and related services business, and Diagnostic Solutions, which includes risk assessment services for life insurers and healthcare IT products. Its brands include Quest Diagnostics, ExamOne, AmeriPath, Dermpath Diagnostics and Quanum. In 2025, Quest generated $11.0 billion in revenue and processed approximately 244 million test requisitions; its network included approximately 2,400 patient service centers. LifeLabs, acquired in 2024, extends its laboratory and digital health operations into Canada. Quest Diagnostics was incorporated in 1990, and its predecessor companies date to 1967. Its website is https://www.questdiagnostics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Health Services
- Headquarters
- SECAUCUS, NJ
- Fiscal year end
- December
- CIK
- 1022079
- SIC
- 8071
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Quest Diagnostics — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Quest Diagnostics’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Quest Diagnostics’s bonds, as funds hold them
Funds report holding 12 issues of Quest Diagnostics’s debt, $878.68M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.37%, maturing 2026 to 2045.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Quest Diagnostics and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Quest Diagnostics's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Quest Diagnostics's last four quarterly filings that the numbers alone won't show?”